New Report on Pharmaceutical & HealthCare by GlobalData11 Jan 2012 • by Natalie Aster
Addiction Control Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The global addiction control therapeutics market (nicotine, alcohol and drug addiction) was valued at $3,657m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.8% to reach $8,320m by 2018. Increasing awareness about the hazards of addiction will encourage more people to seek treatment and would eventually lead to a steady growth in the addiction control therapeutics market.
However, generic incursion, weak late stage pipeline in terms of innovation and recent failure of NicVax (Nicotine Conjugate Vaccine) in Phase III clinical trials will restrict the growth of the market. In the long term, it remains to be seen as to how the initiatives of the governmental and non-governmental organizations can help to control the menace of addiction.
GlobalData estimates the overall addiction control therapeutic pipeline to be strong. There are 55 molecules in different stages of development, which include 13 first-in class molecules. The late stage addiction control pipeline is weak, with only 16.3% of molecules in Phase III development. The addiction control therapeutics pipeline has four vaccines in Phase II development. current treatment options in the addiction control therapeutics market have been moderately successful in meeting the demand. The unmet need in the addiction control market exists in terms of more efficacious medications which are targeted to help people overcome their addiction and promote long-term abstinence.
Anorexia Nervosa Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The global anorexia nervosa therapeutics market was worth $12.7m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 8.9% to $25m by 2018. The future market is set to witness steady growth until 2018, primarily attributed to an increasing patient pool and public awareness of the disorder.
The anorexia nervosa therapeutics has high unmet need as there is currently no approved therapy for the treatment of this disorder. This implies that there is scope for the launch of new products able to capture the anorexia nervosa therapeutics market. The current therapeutic landscape comprises off - label medications that treat only co - morbid conditions such as depression, anxiety, Obsessive Compulsive Disorder (OCD).
Anorexia nervosa therapeutics pipeline is weak with only five molecules in various Phases of development. SUN11031 is the only first - in - class molecule in the late stage of development and it is expected to be launched in Japan in the forecast period. The late stage pipeline has only one molecule with a novel mechanism of action and the other two are generics. Therefore, it is expected that the launch of SUN11031 will not significantly contribute to the growth of the market, leading to steady market growth.
Report Per Price: $3,500 (Single User License)
More new market research reports can be found at GlobalData’s page.
To order the report or ask for sample pages contact email@example.com